Decitabine in the treatment of acute myeloid leukemia in elderly patients

Priya Malik, Amanda F. Cashen

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent that induces differentiation and apoptosis of leukemic cells, is a well-tolerated alternative to aggressive chemotherapy. It is currently FDA-approved for myelodysplastic syndrome, including patients with 20%-30% bone marrow blasts. Recent clinical attention has focused on evaluating decitabine as frontline therapy for untreated high-risk elderly AML patients. A large randomized international phase III study comparing decitabine to supportive care and cytarabine in elderly AML patients demonstrated significantly improved complete remission rates, but the survival difference did not reach significance. Due to this, decitabine did not achieve FDA approval for AML, but continues to be used off-label. Current research is focused on further defining subgroups of elderly AML patients who may derive greater benefit from decitabine therapy and combining it with other low-intensity active agents for AML.

Original languageEnglish
Pages (from-to)53-61
Number of pages9
JournalCancer Management and Research
Issue number1
StatePublished - Feb 3 2014


  • AML
  • Decitabine
  • Elderly


Dive into the research topics of 'Decitabine in the treatment of acute myeloid leukemia in elderly patients'. Together they form a unique fingerprint.

Cite this